US tariff uncertainty
Potential US tariffs on pharmaceutical imports could impact margins; management called it 'hypothetical' and declined to provide specific mitigation strategy.
high · analyst_questionAlkem Laboratories Limited — Q1 FY26
Alkem Laboratories reported a strong Q1 FY26 with revenue of ₹3,371 crore (+11.2% YoY) and EBITDA of ₹739 crore (+21.4% YoY), driven by robust domestic growth (12% YoY) and impr...
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
US price erosion continues
US business faces 3-4% YoY price erosion, which could offset volume gains and pressure margins.
medium · management_commentaryNew business opex drag
CDMO and medtech businesses will incur significant opex (₹50-60 crore per quarter) in H2 FY26, delaying margin expansion.
medium · management_commentarySeasonality and incentive costs
Employee costs rose 15% YoY due to higher incentives; management expects lower growth in subsequent quarters, but volatility remains.
low · data_observation